MCID: CLN045
MIFTS: 62

Colonic Benign Neoplasm

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Colonic Benign Neoplasm

Summaries for Colonic Benign Neoplasm

Disease Ontology: 11 An intestinal benign neoplasm that is located in the colon.

MalaCards based summary: Colonic Benign Neoplasm, also known as metastatic colon cancer nos, is related to colorectal cancer and lynch syndrome. An important gene associated with Colonic Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Tramadol and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Increased cell migration

Related Diseases for Colonic Benign Neoplasm

Diseases related to Colonic Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1468)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer 34.1 TP53 PALB2 MUTYH MRE11 MLH1 MIR200A
2 lynch syndrome 33.6 TP53 PALB2 MUTYH MRE11 MLH1 MIR18A
3 lynch syndrome 1 33.3 PALB2 MLH1 EPCAM CHEK2 ATM
4 familial colorectal cancer 33.2 TP53 MUTYH MLH1
5 familial adenomatous polyposis 33.1 TP53 MUTYH MLH1 KRAS HRAS CTNNB1
6 ascending colon cancer 33.0 MLH1 KRAS HRAS
7 transverse colon cancer 33.0 MLH1 KRAS HRAS
8 rectosigmoid junction neoplasm 32.9 MLH1 KRAS
9 descending colon cancer 32.9 MLH1 KRAS HRAS
10 colorectal cancer, hereditary nonpolyposis, type 6 32.7 MUTYH MLH1
11 colon adenoma 32.6 TP53 MLH1 MIR200A MIR18A MIR143 LGR5
12 colon adenocarcinoma 32.6 TP53 MLH1 KRAS HRAS CTNNB1 BRAF
13 gastric cancer 32.6 TP53 MUTYH MLH1 MIR143 KRAS ERBB3
14 colorectal adenoma 32.6 TP53 MUTYH MLH1 MIR18A MIR143 KRAS
15 muir-torre syndrome 32.5 TP53 MUTYH MLH1 HRAS EPCAM
16 desmoid tumor 32.5 TP53 MUTYH CTNNB1 APC
17 lynch syndrome 5 32.4 MLH1 BRAF APC
18 juvenile polyposis syndrome 32.4 MUTYH MLH1 APC
19 cowden syndrome 1 32.4 TP53 PALB2 MUTYH MLH1 HRAS CTNNB1
20 adenoma 32.4 TP53 MUTYH MLH1 KRAS HRAS CTNNB1
21 diffuse gastric and lobular breast cancer syndrome 32.4 TP53 PALB2 MUTYH MRE11 MLH1 KRAS
22 adenocarcinoma 32.4 TP53 MLH1 KRAS HRAS ERBB3 EPCAM
23 rectum cancer 32.4 TP53 MUTYH MLH1 MIR200A MIR18A MIR143
24 rectal benign neoplasm 32.3 TP53 MLH1 MIR143 KRAS HRAS CTNNB1
25 colitis 32.2 MLH1 CTNNB1 CHEK2 CCR6 BRAF
26 colorectal adenocarcinoma 32.0 TP53 MLH1 MIR18A MIR143 KRAS HRAS
27 mucinous adenocarcinoma 31.8 TP53 MLH1 KRAS HRAS CTNNB1
28 appendix adenocarcinoma 31.8 TP53 KRAS HRAS
29 mismatch repair cancer syndrome 1 31.7 MLH1 CTNNB1 APC
30 inherited cancer-predisposing syndrome 31.7 TP53 PALB2 MUTYH MRE11 MLH1 EPCAM
31 bap1 tumor predisposition syndrome 31.7 TP53 PALB2 MUTYH MRE11 MLH1 EPCAM
32 hepatocellular carcinoma 31.7 TP53 MLH1 MIR200A MIR18A MIR143 LGR5
33 intestinal benign neoplasm 31.7 TP53 MUTYH MLH1 MIR200A MIR18A MIR143
34 breast cancer 31.6 TP53 PALB2 MUTYH MRE11 MLH1 MIR200A
35 cecum carcinoma 31.6 MLH1 KRAS HRAS
36 lung cancer 31.5 TP53 PALB2 MLH1 MIR200A MIR18A MIR143
37 gastrointestinal system disease 31.5 MIR200A MIR18A MIR143 CCR6 APC
38 endometrial cancer 31.5 TP53 MUTYH MLH1 MIR200A KRAS HRAS
39 mismatch repair cancer syndrome 31.5 TP53 PALB2 MUTYH MLH1 KRAS HRAS
40 telangiectasis 31.5 TP53 CHEK2 CCR6 ATM
41 peripheral nervous system disease 31.5 TP53 MIR143 KRAS HRAS CTNNB1 CCR6
42 diffuse gastric cancer 31.5 TP53 PALB2 MUTYH MLH1 KRAS CTNNB1
43 ataxia-telangiectasia 31.5 TP53 MRE11 CHEK2 C11orf65 BRAF ATM
44 signet ring cell adenocarcinoma 31.5 TP53 MLH1 KRAS HRAS CTNNB1
45 pancreatic cancer 31.5 TP53 PALB2 MLH1 MIR143 KRAS HRAS
46 cholangiocarcinoma 31.5 TP53 KRAS CTNNB1 BRAF
47 esophageal cancer 31.4 TP53 MLH1 MIR200A MIR18A MIR143 KRAS
48 ovarian cancer 31.4 TP53 PALB2 MUTYH MRE11 MLH1 MIR200A
49 rectosigmoid cancer 31.4 MUTYH MLH1 KRAS HRAS
50 hematologic cancer 31.4 MLH1 MIR18A MIR143 HRAS CCR6 ATM

Graphical network of the top 20 diseases related to Colonic Benign Neoplasm:



Diseases related to Colonic Benign Neoplasm

Symptoms & Phenotypes for Colonic Benign Neoplasm

GenomeRNAi Phenotypes related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.86 MLH1 MRE11 PALB2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.86 ATM BRAF MLH1 MRE11 PALB2 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.86 ATM C11orf65 CHEK2 MLH1 MRE11 MUTYH
4 Increased cell migration GR00055-A-1 9.46 CTNNB1
5 Increased cell migration GR00055-A-3 9.46 CTNNB1
6 Reduced mammosphere formation GR00396-S 9.17 ATM BRAF CCR6 ERBB3 HRAS KRAS

MGI Mouse Phenotypes related to Colonic Benign Neoplasm:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 APC ATM BRAF CCR6 CHEK2 CTNNB1
2 neoplasm MP:0002006 10.38 APC ATM BRAF CHEK2 CTNNB1 ERBB3
3 nervous system MP:0003631 10.36 APC ATM BRAF CCR6 CHEK2 CTNNB1
4 endocrine/exocrine gland MP:0005379 10.26 APC ATM BRAF CHEK2 CTNNB1 EPCAM
5 normal MP:0002873 10.22 APC BRAF CCR6 CTNNB1 ERBB3 HRAS
6 cellular MP:0005384 10.21 APC ATM BRAF CHEK2 CTNNB1 EPCAM
7 cardiovascular system MP:0005385 10.17 APC ATM BRAF CCR6 CHEK2 CTNNB1
8 embryo MP:0005380 10.16 APC ATM BRAF CTNNB1 EPCAM ERBB3
9 digestive/alimentary MP:0005381 10.13 APC BRAF CTNNB1 EPCAM ERBB3 HRAS
10 immune system MP:0005387 10.03 APC ATM BRAF CCR6 CHEK2 CTNNB1
11 pigmentation MP:0001186 10.02 APC BRAF CTNNB1 ERBB3 KRAS TP53
12 craniofacial MP:0005382 9.95 APC BRAF CTNNB1 HRAS KRAS LGR5
13 mortality/aging MP:0010768 9.83 APC ATM BRAF CHEK2 CTNNB1 EPCAM
14 respiratory system MP:0005388 9.76 BRAF CTNNB1 ERBB3 HRAS KRAS LGR5
15 integument MP:0010771 9.36 APC ATM BRAF CTNNB1 ERBB3 HRAS

Drugs & Therapeutics for Colonic Benign Neoplasm

Drugs for Colonic Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
4
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
5
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
6
Orphenadrine Approved Phase 4 83-98-7 4601
7
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758 135400182
8
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
9
Epirubicin Approved Phase 4 56420-45-2 41867
10
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
15
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
16
Magnesium oxide Approved Phase 4 1309-48-4 14792
17
Tocopherol Approved, Investigational Phase 4 1406-66-2
18
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
19
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
20
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
21
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
22
Tranexamic acid Approved Phase 4 1197-18-8 5526
23
Mitomycin Approved Phase 4 50-07-7 5746
24
Simethicone Approved Phase 4 8050-81-5
25
Rivaroxaban Approved Phase 4 366789-02-8 9875401
26
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
27
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
28
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
29
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
31
Chlorotrianisene Investigational, Withdrawn Phase 4 569-57-3 11289
32
Tocotrienol Investigational Phase 4 6829-55-6 9929901
33 Acetaminophen, hydrocodone drug combination Phase 4
34
Ketorolac Tromethamine Phase 4
35 Antiparkinson Agents Phase 4
36 Anticonvulsants Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Muscarinic Antagonists Phase 4
39 Cholinergic Antagonists Phase 4
40 Cholinergic Agents Phase 4
41 Folic Acid Antagonists Phase 4
42 Anesthetics Phase 4
43 Neurotransmitter Agents Phase 4
44 Anti-Anxiety Agents Phase 4
45 Analgesics, Opioid Phase 4
46 Narcotics Phase 4
47 Hormone Antagonists Phase 4
48 Polyethylene glycol 3350 Phase 4
49 Glucagon-Like Peptide 1 Phase 4
50 Pirinitramide Phase 4

Interventional clinical trials:

(show top 50) (show all 1335)
# Name Status NCT ID Phase Drugs
1 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
2 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
3 Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity Unknown status NCT04269369 Phase 4 5-Fluorouracil
4 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
5 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Unknown status NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
6 Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial Completed NCT00654212 Phase 4
7 Konzentrationen Von Ertapenem in Kolorektalem Gewebe Completed NCT00535652 Phase 4 Ertapenem
8 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
9 Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV Completed NCT00263055 Phase 4 oxaliplatin
10 Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates Completed NCT00628147 Phase 4
11 Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial Completed NCT02078726 Phase 4 Glucagon
12 An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
13 Effect of Postoperative Laxative on Bowel Function After Colonic Surgery Completed NCT00427492 Phase 4 Magnesia;Placebo
14 An Expanded Access Program of AvastinTM (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum Completed NCT02582970 Phase 4 5-Fluorouracil;Bevacizumab;Irinotecan;Oxaliplatin
15 Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX' Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
16 Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery Completed NCT02314871 Phase 4 Piritramide;Morphine
17 Preoperative Use of the High Protein ONS vs Immunoenhancing ONS in Gastrointestinal Cancer Patients Undergoing Surgery Completed NCT03980704 Phase 4 IMPACT;resource protein
18 Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer Completed NCT02231203 Phase 4 Omegaven;Placebo
19 A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
20 Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study Completed NCT02937506 Phase 4 Propofol;Fentanyl Plus Midazolam
21 Clinical Efficacy of Chemotherapy Combined With Cytokine-induced Killer in Treatment of Patients With Colon Cancer Completed NCT03084809 Phase 4 Cytokine-induced killer cells+ FOLFOX4;FOLFOX4
22 Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery Completed NCT00942461 Phase 4
23 Improving Perioperative Pain Management for Laparoscopic Surgery Due to Colon Cancer Using the Ultrasound-guided Transmuscular Quadratus Lumborum Block. A Double Blind, Randomized, Placebo Controlled Trial. Completed NCT03570541 Phase 4 Ropivacaine;Acetaminophen;Morphine;Saline
24 The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery Completed NCT02052557 Phase 4 Bupivacaine;Bupivacaine liposome suspension
25 Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy Completed NCT01169220 Phase 4 Go-Lytely;Go Lytely
26 Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia Completed NCT01373021 Phase 4 Fentanyl;Dexmedetomidine
27 Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial Recruiting NCT05068180 Phase 4 low-dose neuroleptanalgesia;Placebo
28 A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
29 Influence of Argipressin on Blood Loss and Inflammatory Response During Hepatic Resection; a Double-blinded, Randomized Placebo-controlled Trial Recruiting NCT05293041 Phase 4 Argipressin;Placebo
30 Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding Recruiting NCT05345613 Phase 4 Tranexamic acid;Standard
31 Phase IV Multicentric Clinical Trial to Evaluate the Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Mytomicin-C After Complete Surgical Cytoreduction in Patients With Colon Cancer Peritoneal Metastases Recruiting NCT05250648 Phase 4 complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
32 Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial Recruiting NCT04311099 Phase 4 Active drug;Placebo
33 Evaluation of Anticancer Effect of Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer Recruiting NCT03645187 Phase 4 FOLFERI;Folferi and celecoxib
34 Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract Not yet recruiting NCT02688699 Phase 4
35 Evaluation of Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in the Surgical Treatment of Colorectal Cancer Not yet recruiting NCT05303818 Phase 4 Rivaroxaban 10 MG
36 Comparison of Low-volume Versus High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis: a Randomized Non-inferiority Trial Not yet recruiting NCT04709770 Phase 4 2-liters polyethylene glycol with citrate and simethicone;4-liters polyethylene glycol with simethicone
37 Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor Terminated NCT02015923 Phase 4 Chemotherapy- scheme
38 A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Colon Cancer Unknown status NCT00387842 Phase 3
39 Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group Clinical Trial Unknown status NCT02777437 Phase 2, Phase 3 XELOX or FOLFOX chemotherapy
40 The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial Unknown status NCT02598414 Phase 2, Phase 3
41 The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy Unknown status NCT02280278 Phase 3 Adjuvant chemotherapy
42 FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer Unknown status NCT00647530 Phase 2, Phase 3 capecitabine;fluorouracil;oxaliplatin
43 Effect of TCM-TSKSR on Completion Rates of Chemotherapy in Patients With Stage II & III Colon Cancer: A Randomized Placebo-Controlled Clinical Trial Unknown status NCT03716518 Phase 3 Tonifying Spleen and Kidney Sequential Regimen;Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
44 5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03). Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
45 A Randomized Controlled Trial Comparing the Outcomes of Patients Who Undergo Single Port Laparoscopic Colectomy and Conventional Laparoscopic Colectomy for Colonic Neoplasia Unknown status NCT01101672 Phase 2, Phase 3
46 A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer Unknown status NCT01092481 Phase 3 oxaliplatin
47 Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
48 Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts Unknown status NCT00002455 Phase 3
49 Randomized Phase III Study Assessing the Interest of Primary Tumor Resection in Patients With Asymptomatic Colon Cancer and Unresectable Synchronous Liver Metastases. Unknown status NCT02363049 Phase 3 Chemotherapy
50 Complete Mesocolic Excision (CME) With Central Supplying Vessel Ligation (CVL) Compared With Conventional Surgery for Colon Cancer: a Double-blinded Randomized Study Unknown status NCT02526836 Phase 2, Phase 3

Search NIH Clinical Center for Colonic Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Fluorouracil
irinotecan
Irinotecan hydrochloride
Levamisole
Lomustine

Genetic Tests for Colonic Benign Neoplasm

Anatomical Context for Colonic Benign Neoplasm

Organs/tissues related to Colonic Benign Neoplasm:

FMA: Colon
MalaCards : Colon, Lymph Node, Liver, Breast, Prostate, Lung, T Cells

Publications for Colonic Benign Neoplasm

Articles related to Colonic Benign Neoplasm:

(show top 50) (show all 33103)
# Title Authors PMID Year
1
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 62 5
22281684 2012
2
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
3
Oncogenic ERBB3 mutations in human cancers. 5
23680147 2013
4
Unexpected adhesive bowel obstruction after endoscopic submucosal dissection of early sigmoid colon cancer. 62
36466039 2023
5
RNF43 induces the turnover of protease-activated receptor 2 in colon cancer. 62
36468684 2023
6
The burden of colon cancer attributable to modifiable factors-The Norwegian Women and Cancer Study. 62
36054722 2023
7
Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level. 62
36375352 2023
8
Metabolomic Characterization of the Antiproliferative Activity of Bioactive Compounds from Fruit By-Products Against Colon Cancer Cells. 62
36152149 2023
9
ZDHHC9 promotes colon tumor growth by inhibiting effector T cells. 62
36419754 2023
10
Breast metastasis of signet ring cell carcinoma from the colon: a case report. 62
36451153 2022
11
CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA. 62
35130122 2022
12
Energy balance-related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status. 62
36177801 2022
13
Comparison of Robotic and Laparoscopic Colectomies Using the 2019 ACS NSQIP Database. 62
36455896 2022
14
An integrated map of fibroblastic populations in human colon mucosa and cancer tissues. 62
36463319 2022
15
Medullary carcinoma of the colon: A comprehensive analysis of the National Cancer Database. 62
36446307 2022
16
Associations of cigarette smoking, alcohol drinking and body mass index with survival after colorectal cancer diagnosis by anatomic subsite: a prospective patient cohort study in Japan. 62
36007230 2022
17
The Association of Vitamin D3 With Early Anastomotic Leakage in Patients Undergoing Hemicolectomy Surgery. 62
34968156 2022
18
Ursolic and oleanolic acids in combination therapy inhibit migration of colon cancer cells through down-regulation of the uPA/uPAR-dependent MMPs pathway. 62
36191607 2022
19
[Corrigendum] Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathway. 62
36222306 2022
20
CCL26 silence represses colon cancer by inhibiting the EMT signaling pathway. 62
36156375 2022
21
circRNA PLOD2 promotes tumorigenesis and Warburg effect in colon cancer by the miR-513a-5p/SIX1/LDHA axis. 62
36071678 2022
22
The treatment efficacy of three-layered functional polymer materials as drug carrier for orthotopic colon cancer. 62
36101475 2022
23
MiR-17-5p Targets and Downregulates CADM2, Activating the Malignant Phenotypes of Colon Cancer Cells. 62
35696058 2022
24
Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity Patients. 62
36283915 2022
25
Glomerular Microangiopathy with Cellular Crescent-like Formation and Endotheliopathy Due to Ramucirumab Treatment for Metastatic Sigmoid Colon Cancer. 62
35569979 2022
26
The measured distance between tumor cells and the peritoneal surface predicts the risk of peritoneal metastases and offers an objective means to differentiate between pT3 and pT4a colon cancer. 62
36123540 2022
27
Correction to: Impact of preoperative smoking on patients undergoing right hemicolectomies for colon cancer. 62
35895110 2022
28
Tumor-to-tumor metastasis of colon cancer metastasizing to a pancreatic neuroendocrine tumor associated with von Hippel-Lindau disease: a case report. 62
35951216 2022
29
Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer. 62
35980560 2022
30
Long-term Bowel Dysfunction and Decline in Quality of Life Following Surgery for Colon Cancer: Call for Personalized Screening and Treatment. 62
35982522 2022
31
Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. 62
35934636 2022
32
PCDH7 knockdown potentiates colon cancer cells to chemotherapy via inducing ferroptosis and changes in autophagy through restraining MEK1/2/ERK/c-Fos axis. 62
35926236 2022
33
Colon Targeted Eudragit Coated Beads Loaded with Optimized Fluvastatin-Scorpion Venom Conjugate as a Potential Approach for Colon Cancer Therapy: In Vitro Anticancer Activity and In Vivo Colon Imaging. 62
36007556 2022
34
Overexpression of HOXB13 predicts poor prognosis in patients with colon cancer. 62
35715295 2022
35
Gnetum montanum extract induces apoptosis by inhibiting the activation of AKT in SW480 human colon cancer cells. 62
35587342 2022
36
Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective Colon cancer therapy. 62
35942514 2022
37
Antitumoral effect of novel synthetic 8-hydroxy-2-((4-nitrophenyl)thio)naphthalene-1,4-dione (CNN16) via ROS-mediated DNA damage, apoptosis and anti-migratory effect in colon cancer cell line. 62
36208702 2022
38
Retraction statement: High-intensity focused ultrasound inhibits invasion and metastasis of colon cancer cells by enhancing microRNA-124-mediated suppression of STAT3. 62
36377839 2022
39
A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice. 62
36461608 2022
40
Folate decorated lipid chitosan hybrid nanoparticles of 5-fluorouracil for enhanced anticancer efficacy against colon cancer. 62
36174854 2022
41
Nobiletin is capable of regulating certain anti-cancer pathways in a colon cancer cell line. 62
36454256 2022
42
Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer. 62
36454192 2022
43
[What is confirmed in the treatment of colon cancer?] 62
36380005 2022
44
Resveratrol inhibits proliferation and induces apoptosis via the Hippo/YAP pathway in human colon cancer cells. 62
36335870 2022
45
Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. 62
35477539 2022
46
Colon cancer and colorectal cancer: Prevention and treatment by potential natural products. 62
36202214 2022
47
Robotic complete mesocolic excision of right-sided colon cancer with bulky lymph node metastases using the da Vinci® Si™ system: A case report. 62
36311687 2022
48
Identifying novel interactions of the colon-cancer related APC protein with Wnt-pathway nuclear transcription factors. 62
36457029 2022
49
Hypoxia-inducible factors, mTOR, and astrin constitute an integrative regulatory network in colon cancer cells. 62
36111249 2022
50
Successful left hepatic trisectionectomy after portal vein embolization for colon cancer liver metastasis in a patient with right-sided ligamentum teres. 62
36088617 2022

Variations for Colonic Benign Neoplasm

ClinVar genetic disease variations for Colonic Benign Neoplasm:

5 (show all 14)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EPCAM NM_002354.3(EPCAM):c.903+1G>A SNV Pathogenic
1244227 GRCh37: 2:47612350-47612350
GRCh38: 2:47385211-47385211
2 MRE11 NM_005591.4(MRE11):c.1726C>T (p.Arg576Ter) SNV Pathogenic
184445 rs774277300 GRCh37: 11:94180442-94180442
GRCh38: 11:94447276-94447276
3 APC NM_000038.6(APC):c.1370C>A (p.Ser457Ter) SNV Pathogenic
433620 rs1060503333 GRCh37: 5:112157650-112157650
GRCh38: 5:112821953-112821953
4 MLH1 NM_000249.4(MLH1):c.1A>T (p.Met1Leu) SNV Pathogenic
1255698 GRCh37: 3:37035039-37035039
GRCh38: 3:36993548-36993548
5 ATM, C11orf65 NM_000051.4(ATM):c.6415G>T (p.Glu2139Ter) SNV Pathogenic
651311 rs1339238483 GRCh37: 11:108190748-108190748
GRCh38: 11:108320021-108320021
6 MLH1 NM_000249.4(MLH1):c.790+1G>A SNV Pathogenic
90356 rs267607789 GRCh37: 3:37056036-37056036
GRCh38: 3:37014545-37014545
7 PALB2 NM_024675.4(PALB2):c.1671_1674del (p.Ile558fs) MICROSAT Pathogenic
410108 rs1060502734 GRCh37: 16:23646193-23646196
GRCh38: 16:23634872-23634875
8 ERBB3 NM_001982.4(ERBB3):c.850G>A (p.Gly284Arg) SNV Likely Pathogenic
376167 rs1057519803 GRCh37: 12:56481922-56481922
GRCh38: 12:56088138-56088138
9 MUTYH NM_001048174.2(MUTYH):c.420+19_420+31del DEL Likely Pathogenic
406825 rs781222233 GRCh37: 1:45798559-45798571
GRCh38: 1:45332887-45332899
10 CHEK2 NM_007194.4(CHEK2):c.917G>C (p.Gly306Ala) SNV Likely Pathogenic
128089 rs587780192 GRCh37: 22:29095917-29095917
GRCh38: 22:28699929-28699929
11 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Likely Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
12 BRAF NM_004333.6(BRAF):c.1799_1800delinsAA (p.Val600Glu) INDEL Likely Pathogenic
376069 rs121913377 GRCh37: 7:140453135-140453136
GRCh38: 7:140753335-140753336
13 TP53 NM_000546.6(TP53):c.1060C>A (p.Gln354Lys) SNV Uncertain Significance
231485 rs755394212 GRCh37: 17:7573967-7573967
GRCh38: 17:7670649-7670649
14 MLH1 NM_000249.4(MLH1):c.884+3A>C SNV Uncertain Significance
1255699 GRCh37: 3:37059093-37059093
GRCh38: 3:37017602-37017602

Expression for Colonic Benign Neoplasm

Search GEO for disease gene expression data for Colonic Benign Neoplasm.

Pathways for Colonic Benign Neoplasm

Pathways related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 APC ATM BRAF CCR6 CHEK2 CTNNB1
2 13.79 TP53 LGR5 KRAS HRAS ERBB3 CTNNB1
3
Show member pathways
13.75 TP53 PALB2 MUTYH MRE11 MLH1 KRAS
4
Show member pathways
13.48 TP53 KRAS HRAS ERBB3 CTNNB1 BRAF
5
Show member pathways
13.19 TP53 PALB2 MUTYH MRE11 MLH1 CHEK2
6
Show member pathways
12.89 TP53 MRE11 MLH1 KRAS HRAS CHEK2
7
Show member pathways
12.85 KRAS HRAS CTNNB1 BRAF APC
8 12.85 KRAS HRAS ERBB3 CTNNB1 BRAF
9
Show member pathways
12.82 TP53 MIR18A LGR5 CTNNB1 APC
10
Show member pathways
12.75 PALB2 MUTYH MRE11 MLH1 ATM
11 12.7 TP53 HRAS CTNNB1 ATM APC
12
Show member pathways
12.62 PALB2 MUTYH MRE11 MLH1 ATM
13
Show member pathways
12.62 TP53 MLH1 KRAS HRAS CTNNB1 BRAF
14 12.5 TP53 MUTYH MRE11 MLH1 CHEK2 ATM
15
Show member pathways
12.45 TP53 HRAS ERBB3 CTNNB1 BRAF
16
Show member pathways
12.44 TP53 KRAS HRAS ERBB3 CTNNB1 BRAF
17 12.41 BRAF HRAS KRAS TP53
18
Show member pathways
12.4 KRAS HRAS CTNNB1 BRAF
19
Show member pathways
12.37 TP53 MRE11 CHEK2 ATM
20
Show member pathways
12.37 KRAS HRAS ERBB3 CTNNB1 BRAF APC
21
Show member pathways
12.28 TP53 KRAS HRAS ERBB3 CTNNB1 CHEK2
22
Show member pathways
12.21 TP53 KRAS HRAS ERBB3 BRAF
23 12.19 TP53 KRAS HRAS CTNNB1
24
Show member pathways
12.17 BRAF HRAS KRAS TP53
25
Show member pathways
12.1 TP53 MRE11 CHEK2 ATM
26 12.1 TP53 MLH1 KRAS CTNNB1 BRAF APC
27 12.03 KRAS HRAS CTNNB1 APC
28 11.99 APC BRAF ERBB3 KRAS LGR5 TP53
29
Show member pathways
11.89 TP53 MRE11 CHEK2 ATM
30 11.83 TP53 HRAS CTNNB1
31
Show member pathways
11.81 ATM CHEK2 MRE11 TP53
32
Show member pathways
11.8 KRAS HRAS BRAF
33
Show member pathways
11.8 TP53 KRAS HRAS
34
Show member pathways
11.8 ATM CHEK2 MRE11 TP53
35 11.79 TP53 KRAS BRAF
36
Show member pathways
11.76 TP53 CHEK2 ATM
37 11.74 TP53 KRAS HRAS CTNNB1
38 11.74 TP53 KRAS HRAS CTNNB1 ATM APC
39 11.73 HRAS CTNNB1 APC
40 11.68 TP53 MIR18A MIR143 ATM
41 11.68 TP53 MRE11 KRAS CTNNB1 CHEK2 BRAF
42 11.67 TP53 HRAS ATM
43
Show member pathways
11.66 KRAS HRAS BRAF
44
Show member pathways
11.66 TP53 MRE11 KRAS HRAS CTNNB1 BRAF
45
Show member pathways
11.65 BRAF HRAS KRAS
46 11.62 KRAS HRAS ERBB3
47 11.56 TP53 CHEK2 ATM
48 11.54 TP53 PALB2 MRE11 MLH1 CHEK2 ATM
49 11.53 MIR143 ERBB3 CTNNB1
50
Show member pathways
11.51 TP53 CHEK2 ATM

GO Terms for Colonic Benign Neoplasm

Cellular components related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral plasma membrane GO:0016328 9.23 ERBB3 EPCAM CTNNB1 APC

Biological processes related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.34 TP53 PALB2 MRE11 ERBB3 CTNNB1 BRAF
2 positive regulation of gene expression GO:0010628 10.25 TP53 KRAS HRAS ERBB3 CTNNB1 BRAF
3 negative regulation of neuron apoptotic process GO:0043524 10.19 KRAS HRAS ERBB3 BRAF
4 MAPK cascade GO:0000165 10.18 KRAS HRAS CTNNB1 BRAF
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10.08 MLH1 CHEK2 ATM
6 DNA repair GO:0006281 10.08 ATM CHEK2 MLH1 MRE11 MUTYH PALB2
7 thymus development GO:0048538 10.07 ATM BRAF CTNNB1
8 double-strand break repair GO:0006302 10.06 TP53 MRE11 CHEK2 ATM
9 somitogenesis GO:0001756 10.04 ATM PALB2 TP53
10 T cell differentiation in thymus GO:0033077 10.03 TP53 CTNNB1 BRAF
11 double-strand break repair via nonhomologous end joining GO:0006303 10 MRE11 MLH1 ATM
12 embryonic organ development GO:0048568 9.95 TP53 PALB2 CTNNB1
13 signal transduction in response to DNA damage GO:0006975 9.91 CHEK2 ATM
14 signal transduction in response to DNA damage GO:0042770 9.91 CHEK2 ATM
15 reciprocal meiotic recombination GO:0007131 9.89 MRE11 MLH1 ATM
16 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.88 TP53 CHEK2 ATM
17 positive regulation of neuron apoptotic process GO:0043525 9.87 ATM CTNNB1 MIR200A TP53
18 cellular response to gamma radiation GO:0071480 9.86 TP53 HRAS CHEK2 ATM
19 replicative senescence GO:0090399 9.85 TP53 CHEK2 ATM
20 regulation of cell population proliferation GO:0042127 9.85 TP53 LGR5 HRAS ERBB3 CTNNB1 BRAF
21 neuron apoptotic process GO:0051402 9.65 ATM ERBB3 HRAS KRAS TP53
22 response to stress GO:0006950 9.54 MUTYH ATM
23 cellular response to DNA damage stimulus GO:0006974 9.44 TP53 PALB2 MUTYH MRE11 MLH1 CHEK2

Molecular functions related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutSalpha complex binding GO:0032407 8.92 MUTYH MLH1

Sources for Colonic Benign Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....